About CH de Lens
"Le CHL est l’établissement support du GHT. C’est l’hôpital le plus important du Pas-de-Calais en termes d’activité. Il propose, à quelques exceptions près, l’ensemble des spécialités médicales, chirurgicales et obstétricales. Il s’appuie sur un plateau technique conséquent et complet (imagerie, labo, blocs opératoires, consultations, ...), une maternité de niveau 3, et certaines activités généralement limitées aux CHU. Il dispose d’un service d’urgences à très forte activité et reconnu comme centre de recours sur le territoire dans plusieurs domaines."
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
The Lymphoma Academic Research Organisation
5
Celgene
2
Intergroupe Francophone du Myelome
2
ARCAGY/ GINECO GROUP
1
Biotronik France
1
Centre Hospitalier of Chartres
1
Institut National de la Santé Et de la Recherche Médicale, France
1
Lymphoma Study Association
1
Nantes University Hospital
1
University Hospital, Brest
1
University Hospital, Toulouse
1
Clinical Trials at CH de Lens
During the past decade, CH de Lens conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 0 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis
2007-07-01
2017-03-01
Completed
60
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
2010-07-01
2013-11-01
Completed
602
Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP
2009-04-01
2019-09-01
Completed
650
Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients
2010-12-01
2020-05-23
Completed
650
Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
2013-01-01
2022-12-13
Completed
421
R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL
2013-11-01
2025-08-01
Active, not recruiting
623
PREDICTive FactOR of Overall Survival Among Geriatric Assessment Tools and Disease Related Factors in Elderly Patients With High Risk Myelodysplastic Syndromes.
2016-04-20
2020-01-01
Completed
157
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "CH de Lens" #1 sponsor was "The Lymphoma Academic Research Organisation" with 5 trials, followed by "Celgene" with 2 trials
sponsored, "Intergroupe Francophone du Myelome" with 2 trials sponsored, "ARCAGY/ GINECO GROUP" with 1 trials sponsored and "Biotronik France"
with 1 trials sponsored. Other sponsors include 1 different institutions and
companies that sponsored additional 11 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "CH de Lens"
#1 collaborator was "AstraZeneca" with 1 trials as a collaborator, "Bayer" with 1 trials as a collaborator, "Biotronik SE & Co. KG" with 1 trials as a collaborator, "CHU de Nancy" with 1 trials as a collaborator and "Hoffmann-La Roche" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were
collaborators in the rest 7 trials.
Clinical Trials Conditions at CH de Lens
According to Clinical.Site data, the most researched conditions in "CH de Lens" are
"Diffuse Large B-cell Lymphoma" (2 trials), "Multiple Myeloma" (2 trials), "Primary Myelofibrosis" (2 trials), "Acute Respiratory Failure" (1 trials) and "Anemia" (1 trials). Many other conditions were trialed in "CH de Lens" in a lesser frequency.
Clinical Trials Intervention Types at CH de Lens
Most popular intervention types in "CH de Lens" are "Drug" (9 trials), "Other" (5 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.
The name of intervention was led by "Rituximab" (3 trials), "Lenalidomide" (2 trials), "1 year follow-up to assess psychiatric morbidity" (1 trials), "6 months follow-up to assess the prevalence of PTSD symptoms" (1 trials) and "Administration of the IPREA3 questionnaire" (1 trials). Other intervention names were less common.
Clinical Trials Genders at CH de Lens
The vast majority of trials in "CH de Lens" are
16 trials for "All" genders and 1 trials for "Female" genders.
Clinical Trials Status at CH de Lens
Currently, there are NaN active trials in "CH de Lens".
1 are not yet recruiting,
1 are recruiting,
3 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 10 completed trials in CH de Lens,
undefined suspended trials,
and 2 terminated clinical trials to date.
Out of the total trials that were conducted in CH de Lens, 0 "Phase 1"
clinical trials were conducted, 2 "Phase 2" clinical
trials and 7 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 4 trials that are defined as “Not Applicable".